HUP0000343A3 - Use for 1,3-propanediol derivatives to prevent rejection after organ transplantation - Google Patents

Use for 1,3-propanediol derivatives to prevent rejection after organ transplantation

Info

Publication number
HUP0000343A3
HUP0000343A3 HU0000343A HUP0000343A HUP0000343A3 HU P0000343 A3 HUP0000343 A3 HU P0000343A3 HU 0000343 A HU0000343 A HU 0000343A HU P0000343 A HUP0000343 A HU P0000343A HU P0000343 A3 HUP0000343 A3 HU P0000343A3
Authority
HU
Hungary
Prior art keywords
organ transplantation
prevent rejection
propanediol derivatives
propanediol
derivatives
Prior art date
Application number
HU0000343A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUP0000343A2 publication Critical patent/HUP0000343A2/hu
Publication of HUP0000343A3 publication Critical patent/HUP0000343A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Light Receiving Elements (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Peptides Or Proteins (AREA)
HU0000343A 1996-11-19 1997-11-17 Use for 1,3-propanediol derivatives to prevent rejection after organ transplantation HUP0000343A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9624038.7A GB9624038D0 (en) 1996-11-19 1996-11-19 Organic compounds

Publications (2)

Publication Number Publication Date
HUP0000343A2 HUP0000343A2 (hu) 2000-12-28
HUP0000343A3 true HUP0000343A3 (en) 2001-06-28

Family

ID=10803173

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000343A HUP0000343A3 (en) 1996-11-19 1997-11-17 Use for 1,3-propanediol derivatives to prevent rejection after organ transplantation

Country Status (24)

Country Link
US (3) US6274629B1 (cg-RX-API-DMAC10.html)
EP (2) EP1312359B1 (cg-RX-API-DMAC10.html)
JP (2) JP4004070B2 (cg-RX-API-DMAC10.html)
CN (2) CN1146411C (cg-RX-API-DMAC10.html)
AT (2) ATE275947T1 (cg-RX-API-DMAC10.html)
AU (1) AU728420B2 (cg-RX-API-DMAC10.html)
BR (1) BR9713105A (cg-RX-API-DMAC10.html)
CA (1) CA2270952C (cg-RX-API-DMAC10.html)
CZ (1) CZ174999A3 (cg-RX-API-DMAC10.html)
DE (2) DE69730727T2 (cg-RX-API-DMAC10.html)
DK (1) DK1312359T3 (cg-RX-API-DMAC10.html)
ES (2) ES2227726T3 (cg-RX-API-DMAC10.html)
GB (1) GB9624038D0 (cg-RX-API-DMAC10.html)
HU (1) HUP0000343A3 (cg-RX-API-DMAC10.html)
ID (1) ID21568A (cg-RX-API-DMAC10.html)
IL (1) IL129824A (cg-RX-API-DMAC10.html)
NO (1) NO992259L (cg-RX-API-DMAC10.html)
NZ (1) NZ335629A (cg-RX-API-DMAC10.html)
PL (1) PL190348B1 (cg-RX-API-DMAC10.html)
PT (2) PT1312359E (cg-RX-API-DMAC10.html)
RU (1) RU2217136C2 (cg-RX-API-DMAC10.html)
SI (1) SI1312359T1 (cg-RX-API-DMAC10.html)
SK (1) SK284806B6 (cg-RX-API-DMAC10.html)
WO (1) WO1998022100A2 (cg-RX-API-DMAC10.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027798A1 (en) 1998-11-11 2000-05-18 Novartis Ag Production of 2-amino-2-[2-(4-c2-20-alkyl-phenyl)ethyl]propane-1,3-diols
HUP0204069A3 (en) * 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
JP4318921B2 (ja) * 2001-02-22 2009-08-26 ノバルティス アクチエンゲゼルシャフト 移植片の機能発現遅延の処置のための医薬の製造のためのリンパ球ホーミング促進剤の使用
JP4588979B2 (ja) * 2001-04-20 2010-12-01 オプタルモファーマ アクチェンゲゼルシャフト プロドラッグとして使用されうる修飾型シクロスポリン及びその使用
ES2322442T3 (es) * 2001-06-08 2009-06-22 Novartis Ag Tratamiento o profilaxis del rechazo de injertos de celulas productoras de insulina.
GB0117921D0 (en) * 2001-07-23 2001-09-12 Novartis Ag Organic compounds
US7780993B2 (en) * 2001-09-07 2010-08-24 Yeda Research And Development Co. Ltd. Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
US20040136972A1 (en) * 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
GB0125443D0 (en) 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
MXPA04006709A (es) 2002-01-11 2004-10-04 Sankyo Co Derivados de aminoalcohol o derivados de acido fosfonico y composiciones farmaceuticas que los contienen.
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
IL165425A0 (en) * 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
CA2707750A1 (en) 2003-04-08 2004-10-21 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
US7524887B2 (en) 2003-06-06 2009-04-28 Sanofi-Aventis Deutschland Gmbh 2-amino-1,3-propanediol compounds for the treatment of acute pain
EP1484057A1 (en) * 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
US7838562B2 (en) * 2003-06-24 2010-11-23 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
US7074659B2 (en) * 2003-11-13 2006-07-11 Volterra Semiconductor Corporation Method of fabricating a lateral double-diffused MOSFET (LDMOS) transistor
KR20110136901A (ko) 2004-02-24 2011-12-21 상꾜 가부시키가이샤 아미노 알코올 화합물
PL1773307T3 (pl) * 2004-07-30 2015-03-31 Novartis Ag Preparaty 2-amino-1,3-propanodioli i ich analogów
RU2433117C2 (ru) 2005-12-15 2011-11-10 Мицубиси Танабе Фарма Корпорейшн Аминное соединение и его применение в медицинских целях
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
AU2014224237B2 (en) * 2013-03-05 2017-07-20 Biocon Limited A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
US20180250235A1 (en) 2015-09-18 2018-09-06 Sanovel Ilac Sanayi Ve Ticaret A.S. Fingolimod capsule composition
JP2024521882A (ja) * 2021-05-31 2024-06-04 上海雲晟研新生物科技有限公司 フィンゴリモド薬用塩、製造方法、それを含む医薬組成物及び使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904679A (en) * 1972-05-23 1975-09-09 Upjohn Co 15-Methyl and 15-ethyl prostaglandin F{HD 2{331 {0 {B analogs
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
NZ243706A (en) * 1991-07-25 1994-08-26 Idec Pharma Corp Recombinant monkey antibodies, pharmaceutical compositions
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
KR0155015B1 (ko) 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
WO1997024112A1 (en) 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. External preparation
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
EP2030614A1 (en) * 1997-02-27 2009-03-04 Novartis AG Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin

Also Published As

Publication number Publication date
NO992259D0 (no) 1999-05-10
ID21568A (id) 1999-06-24
SK284806B6 (sk) 2005-11-03
CZ174999A3 (cs) 1999-08-11
HK1022639A1 (en) 2000-08-18
WO1998022100A3 (en) 1998-06-25
CA2270952C (en) 2007-09-18
IL129824A0 (en) 2000-02-29
GB9624038D0 (en) 1997-01-08
EP1312359A3 (en) 2004-01-02
CA2270952A1 (en) 1998-05-28
EP0941082A2 (en) 1999-09-15
BR9713105A (pt) 2000-04-11
CN1146411C (zh) 2004-04-21
EP1312359B1 (en) 2007-08-15
JP4004070B2 (ja) 2007-11-07
PT941082E (pt) 2004-12-31
DE69730727T2 (de) 2005-09-22
PL190348B1 (pl) 2005-11-30
NO992259L (no) 1999-05-10
WO1998022100A2 (en) 1998-05-28
PT1312359E (pt) 2007-11-09
CN1293876C (zh) 2007-01-10
IL129824A (en) 2003-07-31
ES2289041T3 (es) 2008-02-01
SK65999A3 (en) 1999-12-10
DE69738033D1 (de) 2007-09-27
US20010056124A1 (en) 2001-12-27
PL333463A1 (en) 1999-12-20
DE69738033T2 (de) 2008-04-30
CN1515253A (zh) 2004-07-28
ES2227726T3 (es) 2005-04-01
EP1312359A2 (en) 2003-05-21
US20030069315A1 (en) 2003-04-10
RU2217136C2 (ru) 2003-11-27
EP0941082B1 (en) 2004-09-15
US6486209B2 (en) 2002-11-26
DK1312359T3 (da) 2007-10-08
ATE275947T1 (de) 2004-10-15
US6274629B1 (en) 2001-08-14
HUP0000343A2 (hu) 2000-12-28
AU728420B2 (en) 2001-01-11
DE69730727D1 (de) 2004-10-21
CN1237906A (zh) 1999-12-08
NZ335629A (en) 2001-09-28
ATE369846T1 (de) 2007-09-15
JP2001503780A (ja) 2001-03-21
JP2004256554A (ja) 2004-09-16
SI1312359T1 (sl) 2008-08-31
AU5483198A (en) 1998-06-10

Similar Documents

Publication Publication Date Title
DE69730039D1 (de) Herztransplantate
AU5219198A (en) Method to prevent transplant rejection
PL331602A1 (en) Pyrido- or pyrimido-substituted 6,6- or 6,7-bicyclic derivatives
DE69635951D1 (de) Doppelt unterstütztes intraluminales transplantat
GB2319250B (en) Derivatives of 6,8-Difluoro-7-Hydroxycoumarin
IL130058A0 (en) 8-Azabicyclo(3.2.1)octane-8-azabicyclo(3.2.1)oct-6-ene-9-azabicyclo(3.3.1)nonane-9-aza-3-oxabicyclo (3.3.1)nonane- and 9-aza-3-thiabicyclo(3.3.1)nonane derivatives their preparation and their use as insecticides
HUP9903965A3 (en) Substituted 6,5-hetero-bicyclic derivatives
ZA977652B (en) Substituted 6,6-hetero-bicyclic derivatives
AU1455095A (en) 1,2,4-oxadiazole derivatives and their use as parasiticides for animals
PL332416A1 (en) Substituted heterocyclic compounds as anticarcinogenic agents
PL329121A1 (en) Substituted derivatives of 1,2,3,4-tetrahydronaphtalene
GB9704428D0 (en) Stable release agents
DE69725182D1 (de) 5H PYRROLO[2,1-c][1,4]BENZODIAZEPIN-3-CARBOXAMIDDERIVATE
AUPN880396A0 (en) Animal model for transplantation
AU3693797A (en) 1,3-dimethyl-5-fluoro-pyrazole-4-carboxamide derivatives, their preparation and their use as microbicides
EP0694538A3 (en) 2-Benzyloxy-4-phenoxy pyrimidine derivatives, process for their preparation and herbicidal compositions containing them
GB2292057B (en) Angler's aid
HUT74716A (en) 3-aryl alkenyl-1,2,4-oxadiazole derivatives and their use as parasiticides for animals
AU6623796A (en) Improvements in or relating to fishing
HU9701463D0 (en) Arrangements for harvesting legomes
IL129715A0 (en) Substituted benzo (1,4) dioxanes as antiobesity agents
IL147099A0 (en) New use for 1,3-propanediol derivatives
KR960016046U (ko) 밤낚시용 렌턴 꽂이구
PL316109A1 (en) Skin transplantation instrument
GB9713945D0 (en) Improvements relating to tissue transplantation

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees